RBC Capital analyst Shagun Singh raised the firm’s price target on Penumbra (PEN) to $355 from $325 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that its U.S. VTE business continues to see strong traction and remains a notable driver in 2026. The firm expects U.S. VTE segment, with new launches and recently presented data, to contribute to positive uptake for this division.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $359 from $355 at Canaccord
- Penumbra: Top Pick for 2026 with Strong Growth Catalysts and Margin Improvements
- Penumbra price target raised to $345 from $310 at Baird
- Penumbra upgraded to Buy from Neutral at Citi
- Penumbra’s Promising Growth: Buy Rating Backed by Strong Portfolio and Technological Advancements